Pharmacovigilance Manager
in health
A Pharmacovigilance Manager owns drug safety surveillance in UK pharma biotech and CROs turning real-world signals into decisions that protect patients.
A Pharmacovigilance Manager makes sure a company detects, evaluates, and acts on the safety risks tied to its medicines or medical products once real patients are using them. In plain terms, they run the safety surveillance function that turns scattered real-world signals (side effects, adverse events, complaints, literature reports) into decisions the business can defend to regulators, partners, and patients. In UK life sciences this work sits inside a defined regulatory frame: the Medicines and Healthcare products Regulatory Agency (MHRA), the Good Pharmacovigilance Practices (GVP) modules, and the Yellow Card scheme that collects safety reports nationally.
The role exists because every medicine that reaches a patient can cause harm that was not fully visible in trials. A rare interaction, an off-label pattern, a manufacturing issue, a signal that only shows up across thousands of cases: pharmacovigilance is how a company catches these early and proves it is watching. A Pharmacovigilance Manager is accountable for whether that system actually works day to day, not just on paper for the next inspection.
Ownership comes first. A strong Pharmacovigilance Manager is the person leadership relies on to say: this is our current benefit-risk position, this is what we know, this is what we do not, and this is what we are doing next. Methods, databases, and standard operating procedures matter, but they sit under that accountability.
How this role differs in health and life sciences
In many sectors, risk management is about uptime, fraud, or data loss. In life sciences the stakes are direct: a missed signal can mean patient harm, a regulatory finding, a product recall, or a label that no longer reflects reality. The work is also legally mandated. Under UK rules every Marketing Authorisation Holder must run a pharmacovigilance system and name a Qualified Person for Pharmacovigilance (the QPPV), and the MHRA can inspect that system at any time.
That shapes the operating model. A Pharmacovigilance Manager works where evidence is incomplete, case reports are messy, and deadlines are fixed by regulation rather than by the team. Expedited reports for serious cases run to tight statutory clocks. Periodic reports (the PSUR or PBRER for marketed products, the DSUR for products in trials) have hard submission dates. The risk management plan (RMP) has to stay current as the safety profile evolves. Getting the science right is not enough: it has to be done on time and be fully traceable.
The setting also moves the work around. In Big Pharma the role is usually one specialised seat in a large global safety function, often deep in signal detection, aggregate reporting, or a single therapy area. In a mid-cap or biotech the same title can mean running the whole operation across a small portfolio, including first-in-human safety for novel products. In a CRO (IQVIA, Parexel, ICON and others) the Pharmacovigilance Manager oversees case processing delivered for multiple sponsor clients, where volume and audit-readiness are everything. Medical device vigilance and digital health products bring their own reporting duties, but the centre of gravity for this role is medicines.
Core responsibilities in health and life sciences
Day to day, the Pharmacovigilance Manager is accountable for whether safety information is captured consistently, assessed correctly, and escalated fast enough to prevent repeat harm. They set how individual case safety reports (ICSRs) are received, triaged, coded in MedDRA, assessed for causality and seriousness, and reported to the MHRA and other authorities inside the regulatory clocks.
- Own the intake of adverse events and safety complaints across every channel: clinicians, patients, the Yellow Card scheme, medical information lines, partners, and literature screening.
- Run signal detection and management, deciding what counts as a genuine safety signal worth formal evaluation versus background noise, using disproportionality analysis and observed-versus-expected review.
- Author or oversee aggregate safety reports (PSUR, PBRER, DSUR) and keep the risk management plan aligned with the current benefit-risk picture.
- Manage the safety database (Argus, ARISg, or Veeva Vault Safety) so case data stays clean, queryable, and inspection-ready.
- Maintain the pharmacovigilance system master file and prepare the function for MHRA inspections and partner audits.
- Support or deputise for the QPPV, escalating serious or unexpected findings without delay.
- Oversee vendors and partners who handle outsourced case processing, and keep safety data exchange agreements working across organisations.
A large part of the job is judgement under constraints. You rarely get perfect data: reports arrive incomplete, timelines are tight, and operational teams are stretched. The Pharmacovigilance Manager decides what needs immediate action, what warrants formal investigation, and what can be monitored against defined thresholds. They also own the trade-off between speed and certainty: moving fast enough to protect patients while keeping the discipline that makes a decision defensible to an inspector months later.
In practice they spend as much time aligning people as managing process: negotiating responsibilities with medical and regulatory colleagues, pushing for label or RMP changes when the data demands it, challenging metrics that hide under-reporting, and preparing the company to respond calmly to external scrutiny.
Skills and competencies for health and life sciences
| Core skill | Health and life sciences requirement | Reason or impact |
|---|---|---|
| GVP and regulatory fluency | Working command of the GVP modules, MHRA expectations, and reporting clocks for ICSRs and aggregate reports | Keeps the company compliant and inspection-ready and prevents missed statutory deadlines that trigger findings |
| Signal detection judgement | Telling a real safety signal from noise using disproportionality and observed-versus-expected analysis | Surfaces emerging risks early before they become systemic harm or a forced label change |
| Case assessment under uncertainty | Sound causality and seriousness calls on incomplete reports with messy clinical context | Prevents both under-reaction (patient harm) and over-reaction (avoidable disruption and lost trust) |
| Safety database competence | Hands-on Argus ARISg or Veeva Vault Safety for case processing coding and querying | The single biggest skills-based pay driver and the basis of clean auditable data |
| Aggregate report writing | Authoring or owning PSUR PBRER DSUR and keeping the risk management plan current | Bridges line-level case work to management scope and protects the marketing authorisation |
| Audit and inspection readiness | Documentation and communication that is traceable consistent and defensible | Protects the organisation during MHRA inspections partner due diligence and safety data exchange reviews |
| Vendor and partner oversight | Managing outsourced PV operations and safety data exchange agreements across organisations | Stops safety accountability being dropped between sponsor and CRO in shared delivery models |
Salary ranges in UK health and life sciences
Pharmacovigilance pay is shaped less by raw years and more by how much risk the person genuinely owns. The biggest drivers are: hands-on safety database experience, whether you author aggregate reports and run signal detection, proximity to or cover for the QPPV, therapy-area complexity (oncology rare disease vaccines and biologics carry a premium), employer type, and leadership scope. Location matters less here than in most pharma roles because so much of the work happens in cloud-hosted safety databases. The London premium is real but modest (in the region of 8 to 12 per cent), and the established pharma corridors of Cambridge Hertfordshire and the North West often pay at or above London for senior safety work.
| Experience level | Estimated annual salary range | What drives compensation |
|---|---|---|
| Junior | London & South East: £32,000-£48,000 Rest of UK: £30,000-£44,000 | Drug safety associate or officer work: case intake triage MedDRA coding and reporting under supervision. Higher with safety-database time |
| Mid-level | London & South East: £42,000-£62,000 Rest of UK: £38,000-£58,000 | Independent case processing signal-associate work and quality checks. Pay rises with aggregate-report exposure |
| Senior | London & South East: £55,000-£78,000 Rest of UK: £50,000-£72,000 | Owns signal detection investigations and aggregate authorship. Higher when the role is the safety authority for a product or portfolio |
| Lead | London & South East: £70,000-£100,000 Rest of UK: £65,000-£92,000 | PV Manager scope: line management process ownership inspection readiness and vendor oversight across a portfolio |
| Head / Director | London & South East: £120,000-£220,000 Rest of UK: £110,000-£190,000 | Accountable for the pharmacovigilance system across products and markets often with named QPPV accountability and equity at scale-ups |
Sources: PharmaLink Academy UK PV salary guide (May 2026), SalaryExpert UK, and SimplyHired UK aggregate data. Treat these as a guide; real offers move with employer, setting and specialism.
Add-ons vary by employer maturity and risk profile. Big Pharma sponsors typically pair the highest base with bonus, pension uplift, and structured benefits; biotechs often run a lower base with equity that can matter at exit; CROs sit lower on base but offer faster progression and broader case mix. Named QPPV cover changes the picture entirely: experienced contract QPPVs command roughly £1,200 to £2,000 per day, and permanent QPPV-level packages run well into six figures. On-call or out-of-hours allowances appear where there is a formal expectation to respond to serious safety events outside business hours.
Career pathways
Most people enter UK pharmacovigilance from a life-science degree, pharmacy, nursing, medicine, or biomedical science, then start as a drug safety associate or officer processing cases. There is no compulsory PV-specific licence in the UK; what gets you hired is demonstrable case processing, MedDRA coding, and the ability to speak the language of GVP and signal detection in an interview. Some candidates arrive from clinical research, regulatory affairs, quality, or medical information and move across by taking ownership of safety reporting.
Progression is less about collecting titles and more about widening the radius of accountability. Early on you prove you can run a reliable process. Then you prove you can make difficult causality and signal calls on imperfect data. Then you prove you can shape the system itself: governance, aggregate reporting, audit and inspection readiness, vendor oversight, and risk management strategy. The classic ladder runs from associate to PV scientist to senior PV to PV Manager, then towards QPPV or Operations Lead, and on to Head or Director of Pharmacovigilance.
At the top end the career becomes about organisational trust. You are not only running pharmacovigilance but making it easier for the company to develop and market products safely, pass inspections, scale partnerships, and respond calmly when the real world behaves differently than the trials suggested.
FAQ
Do I need to be a pharmacist or clinician to be a Pharmacovigilance Manager?
Not always. Many Pharmacovigilance Managers come from life-science or biomedical backgrounds and succeed by pairing strong PV fundamentals with the discipline to run an auditable system. Clinical credibility helps, especially for causality assessment and for the QPPV track, but the core requirement is ownership of safety decisions and a working command of GVP and the reporting clocks.
What is the QPPV and how does it relate to this role?
The Qualified Person for Pharmacovigilance is the individual every UK Marketing Authorisation Holder must name to take personal responsibility for the safety system. A Pharmacovigilance Manager often supports or deputises for the QPPV, and moving towards that named role is the main route into the highest pay tier. It is the inflection point of a UK PV career.
What will interviewers test that is specific to life-sciences pharmacovigilance?
Expect scenario questions on ambiguous case reports, causality and seriousness calls, and signal evaluation. They will probe how you handle reporting deadlines, how you prevent under-reporting across channels, how you would prepare for an MHRA inspection, and how comfortable you are in a safety database such as Argus ARISg or Veeva Vault Safety.
Is on-call common for Pharmacovigilance Managers?
It depends on the company and portfolio. On-call is more likely where there is a formal duty to respond rapidly to serious safety events or regulator queries outside business hours. In practice it ranges from light reachable-for-advice cover to a defined rota with strict response times.
Find your next role
If you are looking for your next Pharmacovigilance Manager role across UK pharma biotech and CROs, search open positions on Meeveem and compare scope ownership and safety accountability, not just the title.